TrialInternational journal of hematology2026

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

Koji Izutsu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.